marketshareAI
Theme

Avacta Group

AVCTHealthcare
53.75GBX
3.37%
Market Cap
219.44M
Volume
75k
3% of avg
P/E Ratio
-5.68
EPS (TTM)
-9.46
Beta
-0.45
Day Range
0.00p - 0.00p
52 Week Range
0.00p53.75p72.00p
53.75p

Upcoming Events

September 30, 2025
Avacta Group to announce interim results
October 1, 2025
AIM Awards event where the Technology of the Year Award will be presented
High Impact Event
Late Q4 2025
Expected release of initial data for FAP-Dox (AVA6000) in salivary gland cancer
High Impact Event
17 October 2025
Avacta to present FAP-Dox data at ESMO Congress
High Impact Event
October 19, 2025
Avacta Group's abstract presentation at ESMO Congress
October 20, 2025
Quarterly repayment of convertible bond
High Impact Event
December 2025
IND submission for FAP-EXd (AVA6103)
High Impact Event
Early Q1 2026
Phase 1 trial of AVA6103 to begin
High Impact Event
Q1 2026
Initial data in triple negative breast cancer for FAP-Dox (AVA6000) expected
High Impact Event
Early 2026
Phase 1 trial for FAP-EXd (AVA6103) anticipated to begin
High Impact Event
Early Q2 2026
Planned start of Phase 2 trials for FAP-Dox in salivary gland cancer and triple negative breast cancer
High Impact Event
AVCT
NEUTRAL

Avacta Group Provides Interim Results Update and ESMO Congress Details

The biotechnology company provides details on its upcoming interim results announcement and a change in the presentation at the ESMO Congress.

AVCT
NEUTRAL

Avacta's pre|CISION® Platform Shortlisted for AIM Technology of the Year Award

The biotechnology company has been shortlisted for a prestigious industry award, recognizing the potential of its innovative pre|CISION® platform.

AVCT
NEUTRAL

Avacta Completes Sale of Coris Bioconcept

The life sciences company has announced the completion of the sale of its subsidiary Coris Bioconcept SRL.

AVCT
GOOD

Avacta Secures Funding to Settle Convertible Bond Repayment

The healthcare company has reached an agreement to amend the terms of its convertible bond and raised £3.25 million through an equity fundraise to settle an upcoming repayment.

AVCT
NEUTRAL

Avacta to Present New FAP-Dox Data at ESMO Congress

The biotechnology company will present updated data from the Phase 1a trial of its FAP-Dox cancer therapy at the upcoming ESMO Congress.

AVCT
NEUTRAL

Avacta Completes Transition to Pure-Play Therapeutics Business with Coris Bioconcept Sale

The healthcare company has agreed to sell its Coris Bioconcept SRL subsidiary, completing its transition to a pure-play therapeutics business focused on advancing its pre|CISION® platform.

AVCT
NEUTRAL

Avacta Settles Convertible Bond Installment

The life sciences company has settled a quarterly principal and interest repayment on its convertible bond.

AVCT
NEUTRAL

Avacta Raises £3.25 Million Through Discounted Placing

The biotechnology company has raised £3.25 million through a discounted share placing to settle an upcoming convertible bond repayment.

AVCT
NEUTRAL

Avacta Provides Q2 2025 Business Update

The biotechnology company provides a business update on the progress of its pipeline and changes to its management team and board.

AVCT
NEUTRAL

Avacta Appoints New Chief Medical Officer and Business Development Advisor

The biotechnology company has appointed a new Chief Medical Officer and a business development advisor to strengthen its leadership team.